{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae 1-84 PTH Assay",
        "LIAISON\u00ae 1-84 PTH Control Set",
        "LIAISON\u00ae 1-84 PTH Calibration Verifiers"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K150879",
    "Predicate Device Reference 510(k) Number(s)": [
        "K001411",
        "K033426",
        "K093498"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW",
        "JJX"
    ],
    "Summary Letter Date": "March 31, 2015",
    "Summary Letter Received Date": "April 1, 2015",
    "Submission Date": "March 26, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.1545",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Parathyroid hormone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Parathyroid hormone (1-84)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Two-step, two-site sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Calibration Verifier"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae 1-84 PTH assay, control set, and calibration verifiers for quantitative measurement of parathyroid hormone (1-84) using CLIA technology.",
    "Indications for Use Summary": "Intended for quantitative determination of parathyroid hormone (1-84) in human serum and EDTA plasma for differential diagnosis of hypercalcemia and hypocalcemia due to calcium metabolism disorders; control set and calibration verifiers for quality control and calibration verification of the assay.",
    "fda_folder": "Clinical Chemistry"
}